{
    "organizations": [],
    "uuid": "6487d546eeb35a2351f16a384223c741d6e3ae9f",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-inventiva-fy-revenues-down-31-perc/brief-inventiva-fy-revenues-down-31-percent-idUSFWN1Q21B6",
    "ord_in_thread": 0,
    "title": "BRIEF-Inventiva FY Revenues Down 31 Percent",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 12 (Reuters) - INVENTIVA SA:\n* FULL-YEAR 2017 FINANCIAL INFORMATION AND BUSINESS UPDATE\n* ‍FY REVENUES OF EUR 6.5 MILLION, A 31% DECREASE COMPARED TO 2016​\n* ‍CASH AND CASH EQUIVALENT LEVEL AT EUR 59 MILLION AS OF DECEMBER 31, 2017​\n* ‍NATIVE HEADLINE RESULTS ANTICIPATED SECOND-HALF OF 2019, VERSUS PREVIOUS EXPECTATIONS FOR EARLY 2019\n* PARTNERSHIP WITH ABBVIE PROGRESSING ACCORDING TO PLAN​ * ON ABBVIE PARTNERSHIP, SAYS NEW CLINICAL CANDIDATE ABBV-157 EXPECTED TO ENTER INTO CLINICAL DEVELOPMENT IN 2018\n* YAP-TEAD PROGRAM EXPECTED TO ENTER INTO PHASE I-ENABLING PRECLINICAL DEVELOPMENT IN 2019\n* ON ODIPARCIL PROGRAM: DATA CURRENTLY BEING ANALYSED AND RESULTS EXPECTED TO BE PUBLISHED IN H1 2018\n* ON LANIFIBRANOR PROGRAM : HEADLINE RESULTS ANTICIPATED SECIN H2 2019, VERSUS PREVIOUS GUIDANCE OF EARLY 2019.\n* ON LANIFIBRANOR PROGRAM : COMPLETION OF PATIENT ENROLLMENT, NOW EXPECTED BY END OF 2018\n* ON LANIFIBRANOR PROGRAM : TWO NEW COUNTRIES HAVE BEEN OPENED (CANADA AND AUSTRALIA)\n* ON LANIFIBRANOR PROGRAM : TWO ADDITIONAL COUNTRIES ARE ALSO IN THE PROCESS OF JOINING TRIAL Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-02-13T01:26:00.000+02:00",
    "crawled": "2018-02-13T15:58:48.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "inventiva",
        "sa",
        "financial",
        "information",
        "business",
        "update",
        "revenue",
        "eur",
        "million",
        "decrease",
        "compared",
        "cash",
        "equivalent",
        "level",
        "eur",
        "million",
        "december",
        "headline",
        "result",
        "anticipated",
        "versus",
        "previous",
        "expectation",
        "early",
        "partnership",
        "abbvie",
        "progressing",
        "according",
        "abbvie",
        "partnership",
        "say",
        "new",
        "clinical",
        "candidate",
        "expected",
        "enter",
        "clinical",
        "development",
        "program",
        "expected",
        "enter",
        "phase",
        "preclinical",
        "development",
        "odiparcil",
        "program",
        "data",
        "currently",
        "analysed",
        "result",
        "expected",
        "published",
        "h1",
        "lanifibranor",
        "program",
        "headline",
        "result",
        "anticipated",
        "secin",
        "h2",
        "versus",
        "previous",
        "guidance",
        "early",
        "lanifibranor",
        "program",
        "completion",
        "patient",
        "enrollment",
        "expected",
        "end",
        "lanifibranor",
        "program",
        "two",
        "new",
        "country",
        "opened",
        "canada",
        "australia",
        "lanifibranor",
        "program",
        "two",
        "additional",
        "country",
        "also",
        "process",
        "joining",
        "trial",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}